| Autor: |
Reyes-Ruiz JM; Department of Research, Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional 'Adolfo Ruiz Cortines', Instituto Mexicano del Seguro Social (IMSS), Veracruz 91897, Mexico., García-Hernández O; Department of Internal Medicine, Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional 'Adolfo Ruiz Cortines', Instituto Mexicano del Seguro Social (IMSS), Veracruz 91897, Mexico., Martínez-Mier G; Department of Research, Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional 'Adolfo Ruiz Cortines', Instituto Mexicano del Seguro Social (IMSS), Veracruz 91897, Mexico., Osuna-Ramos JF; Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán 80019, Mexico., De Jesús-González LA; Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico., Farfan-Morales CN; Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana (UAM), Unidad Cuajimalpa, Mexico City 05348, Mexico., Palacios-Rápalo SN; Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico., Cordero-Rivera CD; Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico., Ordoñez-Rodríguez T; Department of Internal Medicine, Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional 'Adolfo Ruiz Cortines', Instituto Mexicano del Seguro Social (IMSS), Veracruz 91897, Mexico., Ángel RMD; Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico. |
| Abstrakt: |
COVID-19 has a mortality rate exceeding 5.4 million worldwide. The early identification of patients at a high risk of mortality is essential to save their lives. The AST-to-lymphocyte ratio index (ALRI) is a novel biomarker of survival in patients with hepatocellular carcinoma, an organ susceptible to SARS-CoV-2 infection. For this study, the prognostic value of ALRI as a marker of COVID-19 mortality was evaluated. For this purpose, ALRI was compared with the main biomarkers for COVID-19 mortality (neutrophil-to-lymphocyte ratio [NLR], systemic immune-inflammation index [SII], platelet-to-lymphocyte ratio [PLR], lactate dehydrogenase (LDH)/lymphocyte ratio [LDH/LR]). A retrospective cohort of 225 patients with SARS-CoV-2 infection and without chronic liver disease was evaluated. In the non-survival group, the ALRI, NLR, SII, and LDH/LR were significantly higher than in the survival group ( p corrected < 0.05). ALRI had an area under the curve (AUC) of 0.81, a sensitivity of 70.37%, and a specificity of 75%, with a best cut-off value >42.42. COVID-19 patients with high ALRI levels had a mean survival time of 7.8 days. Multivariate Cox regression revealed that ALRI > 42.42 (HR = 2.32, 95% CI: 1.35-3.97; p corrected = 0.01) was a prognostic factor of COVID-19 mortality. These findings prove that ALRI is an independent predictor of COVID-19 mortality and that it may help identify high-risk subjects with SARS-CoV-2 infection upon admission. |
